HABA Laboratories, Inc. (JP:4925)

:4925

4925

HABA Laboratories, Inc.

RESEARCH TOOLSreports

HABA Laboratories, Inc. (4925) Price & Analysis

Compare

1 Followers

4925 Stock Chart & Stats

¥1660.00

-¥21.00(-1.26%)

At close: Jan 08 4:00 PM EST

¥1660.00

-¥21.00(-1.26%)

Day’s Range― - ―

52-Week Range¥1,520.00 - ¥1,870.00

Previous CloseN/A

Volume6.60K

Average Volume (3M)2.14K

Market Cap

¥6.81B

Enterprise Value¥3.44B

Total Cash (Recent Filing)¥4.48B

Total Debt (Recent Filing)¥1.56B

Price to Earnings (P/E)12.5

Beta0.26

Next Earnings

May 08, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.38%

Share Statistics

EPS (TTM)34.53

Shares Outstanding3,935,000

10 Day Avg. Volume2,940

30 Day Avg. Volume2,136

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)0.74

Price to Sales (P/S)0.55

P/FCF Ratio4.44

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetLow financial leverage (debt ~0.20x equity) and a substantial equity base provide durable financial flexibility. This conservative capital structure reduces insolvency risk, supports incremental investment or buybacks, and helps the company absorb shocks while pursuing its turnaround over the next several quarters.

Improved Cash GenerationMaterial strengthening of operating and free cash flow in FY2025 means the business can fund operations, modest capex, and shareholder returns from internal cash. Sustained positive FCF enhances financial independence and underpins a multi-quarter recovery if the improved run-rate persists.

High Gross Margins & Profitability ReboundMid-60s gross margins and a return to positive earnings indicate strong product-level economics and pricing power. Durable margin strength supports operating leverage and profit convertibility of revenue growth, improving resilience and the likelihood that earnings can remain positive if sales stabilize.

Bears Say

Revenue ContractionA persistent top-line decline (≈-1.9% YoY in FY2025) undermines scale advantages and limits the ability to absorb fixed costs. If revenue contraction continues, it could cap long-term margin expansion, constrain reinvestment, and slow the pace of the company’s recovery across multiple quarters.

Historical Cash Flow VolatilityWhile FCF turned positive in FY2025, prior years showed negative operating and free cash flow. This volatility reduces confidence in durability of the current improvement, making multi-quarter planning, consistent dividends, or sustained reinvestment riskier until a stable trend is proven.

Modest Returns Vs. Past PeaksROE around 6% reflects only a partial recovery versus historical peaks, indicating the company has yet to fully regain prior capital efficiency. Lower returns can limit organic growth funding and reduce the margin for error if revenues weaken, pressuring long-term shareholder value creation.

4925 FAQ

What was HABA Laboratories, Inc.’s price range in the past 12 months?

HABA Laboratories, Inc. lowest stock price was ¥1520.00 and its highest was ¥1870.00 in the past 12 months.

What is HABA Laboratories, Inc.’s market cap?

HABA Laboratories, Inc.’s market cap is ¥6.81B.

When is HABA Laboratories, Inc.’s upcoming earnings report date?

HABA Laboratories, Inc.’s upcoming earnings report date is May 08, 2026 which is in 40 days.

How were HABA Laboratories, Inc.’s earnings last quarter?

HABA Laboratories, Inc. released its earnings results on Feb 06, 2026. The company reported ¥34.53 earnings per share for the quarter, beating the consensus estimate of N/A by ¥34.53.

Is HABA Laboratories, Inc. overvalued?

According to Wall Street analysts HABA Laboratories, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does HABA Laboratories, Inc. pay dividends?

HABA Laboratories, Inc. pays a Annually dividend of ¥40 which represents an annual dividend yield of 2.38%. See more information on HABA Laboratories, Inc. dividends here

What is HABA Laboratories, Inc.’s EPS estimate?

HABA Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does HABA Laboratories, Inc. have?

HABA Laboratories, Inc. has 3,935,000 shares outstanding.

What happened to HABA Laboratories, Inc.’s price movement after its last earnings report?

HABA Laboratories, Inc. reported an EPS of ¥34.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.173%.

Which hedge fund is a major shareholder of HABA Laboratories, Inc.?

Currently, no hedge funds are holding shares in JP:4925

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

HABA Laboratories, Inc.

HABA Laboratories,Inc. manufactures and sells skin care, and hair and body care products in Japan and internationally. Its skin care products include cleansers/face washes, toners, special care products, and squalane oils; and hair and body care products comprise shampoos, conditioners, soaps, and hair and hand treatment products. The company sells its products through mail order, shops, drug/variety stores, and internet. It has approximately 70 HABA shops located in department stores, shopping malls, etc. HABA Laboratories,Inc. was founded in 1983 and is headquartered in Tokyo, Japan.